![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Resistance analysis of long-acting lenacapavir in highly
treatment-experienced people with HIV after 26 weeks of treatment
|
|
|
EACS 2021 Oct 27-30
N. Margot 1; L. VanderVeen1; V. Naik1; S. Chang1; P.C. Parvangada1; R. Martin1; H. Dvory-Sobol2; M. Rhee2; C. Callebaut1
1Gilead Sciences Inc., Clinical Virology, Foster City, United States; 2Gilead Sciences Inc., Clinical Research, Foster City, United States
![1028211](../images/102821/102821-3/1028211.gif)
![1028212](../images/102821/102821-3/1028212.gif)
![1028213](../images/102821/102821-3/1028213.gif)
![1028214](../images/102821/102821-3/1028214.gif)
![1028215](../images/102821/102821-3/1028215.gif)
![1028216](../images/102821/102821-3/1028216.gif)
![1028217](../images/102821/102821-3/1028217.gif)
![1028218](../images/102821/102821-3/1028218.gif)
![1028219](../images/102821/102821-3/1028219.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|